SciClone Pharmaceuticals (Holdings) Limited (SCCPF)

0.8301 0.0000 (0.00%) At close: 01:32PM EDT

SciClone Pharmaceuticals (Holdings) Limited

Central Plaza
22nd Floor 381 Middle Huaihai Road
Shanghai
China
86 21 2319 3800
https://www.sciclone.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 860

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Hong Zhao	CEO, President & Executive Director	1.1M	N/A	1963
Ms. Rongrong Pan	Company Secretary, CFO & Executive Director	N/A	N/A	1979
Mr. Chihwen Shao	VP & Head of Technical Operations and Pharmacovigilance	N/A	N/A	1963
Mr. Min Jia	VP & Head of Immunization Business Unit	N/A	N/A	1971
Mr. Yansong Chang	VP & GM of Oncology Business Unit	N/A	N/A	1969
Mr. Mingxiang Wu	VP and Head of Market Access & Commercial Operation (MACO) Department	N/A	N/A	1967
Dr. Xiaoning Guo	VP, Head of Research & Development Department and Chief Medical Officer	N/A	N/A	1978
Mr. Lianzong Wu	VP and Head of Registration & Pharmaceutical Affairs Department	N/A	N/A	1976
Dr. Li Mao M.D.	VP, GM of Research and Development & Chief Medical Officer	N/A	N/A	1957
Dr. Min Wu	VP & Chief Business Development Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of chronic hepatitis B. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma. The company's pipeline products comprise Vibativ for the treatment of hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic, which treats solid tumors; PEN-866, a drug conjugate for solid tumors; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.

Corporate Governance

SciClone Pharmaceuticals (Holdings) Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.